

**AMENDMENTS TO THE CLAIMS**

This listing of the claims will replace all prior versions, and listings, of the claims in the application.

**Listing of Claims**

1. (previously presented) A method for inducing apoptosis in an activated T cell in a subject, comprising administering to the subject an effective amount of an anti-CTLA4 antibody, or fragment thereof, which binds to an epitope on a CTLA4 molecule, said epitope comprising the amino acid sequence (Xaa)<sub>n</sub>-Leu-Thr-Phe-Leu-Asp-Asp-(Xaa)<sub>n</sub> (SEQ ID NO:33), wherein Xaa is any amino acid and n=0-20, and wherein said anti-CTLA4 antibody or fragment thereof stimulates a CTLA4-associated apoptotic signal in the T cell.
2. (canceled)
3. (previously presented) The method of claim 1, further comprising administering to the subject at least one second agent that inhibits a costimulatory signal in the T cell, wherein the second agent is selected from the group consisting of an anti-CD28 Fab fragment, anti-B7-1 blocking antibodies, anti-B7-2 blocking antibodies, soluble CD28, soluble B7-1, and soluble B7-2.
- 4-6. (canceled)
7. (previously presented) The method of claim 1, wherein the subject suffers from an autoimmune disease.
- 8-14. (canceled)
15. (previously presented) A method for treating a subject suffering from an autoimmune disease, comprising administering to the subject an effective amount of an anti-CTLA4 antibody, or fragment thereof, which binds to an epitope on a CTLA4 molecule, said epitope comprising the amino acid sequence (Xaa)<sub>n</sub>-Leu-Thr-Phe-Leu-Asp-Asp-(Xaa)<sub>n</sub> (SEQ ID NO:33), wherein Xaa is any amino acid and n=0-20.